228 related articles for article (PubMed ID: 31705171)
1. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
Montes P; Bernal M; Campo LN; González-Ramírez AR; Jiménez P; Garrido P; Jurado M; Garrido F; Ruiz-Cabello F; Hernández F
Cancer Immunol Immunother; 2019 Dec; 68(12):2015-2027. PubMed ID: 31705171
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA; McLemore AF; Aldrich AL; Komrokji RS; McGraw KL; Dhawan A; Geyer S; Hou HA; Eksioglu EA; Sullivan A; Warren S; MacBeth KJ; Meggendorfer M; Haferlach T; Boettcher S; Ebert BL; Al Ali NH; Lancet JE; Cleveland JL; Padron E; List AF
Blood; 2020 Dec; 136(24):2812-2823. PubMed ID: 32730593
[TBL] [Abstract][Full Text] [Related]
3. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
[TBL] [Abstract][Full Text] [Related]
4. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
5. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
6. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
7. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH
Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
Martín-Izquierdo M; Abáigar M; Hernández-Sánchez JM; Tamborero D; López-Cadenas F; Ramos F; Lumbreras E; Madinaveitia-Ochoa A; Megido M; Labrador J; Sánchez-Real J; Olivier C; Dávila J; Aguilar C; Rodríguez JN; Martín-Nuñez G; Santos-Mínguez S; Miguel-García C; Benito R; Díez-Campelo M; Hernández-Rivas JM
Haematologica; 2021 Aug; 106(8):2215-2223. PubMed ID: 32675227
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
Front Immunol; 2021; 12():665541. PubMed ID: 33986753
[TBL] [Abstract][Full Text] [Related]
12. Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.
Montes P; Kerick M; Bernal M; Hernández F; Jiménez P; Garrido P; Márquez A; Jurado M; Martin J; Garrido F; Ruiz-Cabello F
Oncotarget; 2018 Dec; 9(97):36929-36944. PubMed ID: 30651926
[TBL] [Abstract][Full Text] [Related]
13. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of clonal evolution in myelodysplastic syndromes.
Makishima H; Yoshizato T; Yoshida K; Sekeres MA; Radivoyevitch T; Suzuki H; Przychodzen B; Nagata Y; Meggendorfer M; Sanada M; Okuno Y; Hirsch C; Kuzmanovic T; Sato Y; Sato-Otsubo A; LaFramboise T; Hosono N; Shiraishi Y; Chiba K; Haferlach C; Kern W; Tanaka H; Shiozawa Y; Gómez-Seguí I; Husseinzadeh HD; Thota S; Guinta KM; Dienes B; Nakamaki T; Miyawaki S; Saunthararajah Y; Chiba S; Miyano S; Shih LY; Haferlach T; Ogawa S; Maciejewski JP
Nat Genet; 2017 Feb; 49(2):204-212. PubMed ID: 27992414
[TBL] [Abstract][Full Text] [Related]
15. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
18. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
19. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R
Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919
[TBL] [Abstract][Full Text] [Related]
20. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
